Table 2.
Adverse events, cytokine release syndrome, and neurologic toxic effects related to trial regimen
| Variable | All patients (N = 12) | |
|---|---|---|
| Any-grade | Grade 3 or higher | |
| Number of patients (%) | ||
| Adverse event | ||
| Any | 12 (100) | 12 (100) |
| Hematologic | 12 (100) | 12 (100) |
| Leukopenia | 12 (100) | 12 (100) |
| Neutropenia | 12 (100) | 12 (100) |
| Anemia | 10 (83) | 6 (50) |
| Thrombocytopenia | 3 (25) | 3 (25) |
| Lymphocytopenia | 12 (100) | 12 (100) |
| Platelet count increased | 1 (8) | 0 (0) |
| Leukocytosis | 1 (8) | 0 (0) |
| Neutrophilia | 1 (8) | 0 (0) |
| Gastrointestinal | 4 (33) | 1 (8) |
| Nausea and vomiting | 3 (25) | 0 (0) |
| Diarrhea | 4 (33) | 1 (8) |
| Infectious | 7 (58) | 7 (58) |
| Upper respiratory infection | 1 (8) | 1 (8) |
| CMV infection | 5 (42) | 5 (42) |
| Urinary infection | 4 (33) | 3 (25) |
| Oral herpes | 1 (8) | 0 (0) |
| Pneumonia | 1 (8) | 1 (8) |
| EBV infection | 1 (8) | 0 (0) |
| BKV infection | 1 (8) | 0 (0) |
| Other | ||
| Flu like symptoms | 5 (42) | 0 (0) |
| Pyrexia | 12 (100) | 0 (0) |
| Hypotension | 1 (8) | 0 (0) |
| Expectoration | 1 (8) | 0 (0) |
| AST increased | 3 (25) | 0 (0) |
| ALT increased | 2 (17) | 1 (8) |
| Blood LDH increased | 1 (8) | 0 (0) |
| APTT prolonged | 1 (8) | 0 (0) |
| Coagulation disorder | 1 (8) | 1 (8) |
| Hematuria | 2 (17) | 0 (0) |
| Hypocalcemia | 1 (8) | 0 (0) |
| Hypokalemia | 1 (8) | 1 (8) |
| Blood fibrinogen decreased | 1 (8) | 0 (0) |
| NT-proBNP increased | 2 (17) | 0 (0) |
| Myocardial strain | 1 (8) | 0 (0) |
| Hypogammaglobulinemia | 11 (92) | 0 (0) |
| Cytokine release syndrome | 12 (100) | 0 (0) |
| Neurologic toxic effect | 0 (0) | 0 (0) |
CMV cytomegalovirus infection, BKV BK virus, EBV Epstein–Barr virus, APTT activated partial thromboplastin time, NT-proBNP N-terminal pro-brain natriuretic peptides, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase